| Value | ₹600.0 Cr |
|---|
BSE filing, NSE: ARVIND. Summary written from the filing by ALFA Finder's alert engine.
Arvind Ltd: key numbers
- Share price
- ₹490.60
- Market cap
- ₹13,346 Cr
- Revenue (annual)
- ₹9,303 Cr
- Net profit (annual)
- ₹413.9 Cr
- P/E (TTM)
- 29.1×Sector 50.0×
- Promoter holding
- 38.09%-1.44% QoQ
- FII holding
- 15.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Arvind Ltd
All →Arvind Earnings Call Transcript: Key Takeaways
Arvind delivered record revenue and EBITDA despite geopolitical disruption. Advanced Materials is becoming a primary engine, diversifying the earnings portfolio away from cyclical textiles.
- Call
- Guides 15% growth
Arvind Other Announcement
Arvind Ltd filed its quarterly Monitoring Agency Report confirming full utilization of Rs.500 crore QIP proceeds with no deviations. The report is a routine SEBI-mandated compliance filing.
Arvind Investor Presentation: Key Takeaways
Q2 FY27 record revenue ₹2919 Cr (+23% YoY), EBITDA ₹331 Cr (+27%), margin 11.4%; PAT pre-exceptional ₹123 Cr (+16%). AMB record revenue ₹805 Cr; Dalco-GFT consolidated.
Arvind Results Update
Arvind's Q2 FY27 revenue hit ₹2,919 Cr and EBITDA ₹331 Cr, growing 23% and 27% YoY. Varanasi garmenting plant commissioned; credit upgraded to AA.
- garmenting facility revenue capacity
- 250 ₹ Cr revenue at full utilization
Arvind Q2 FY27 Results: Net Profit ₹151.6 Cr, Up 42.1% YoY
Arvind Ltd reported revenue from operations of ₹2,919 Cr (+23.1% YoY) and net profit of ₹151.6 Cr (+42.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹151.6 Cr · +42.1% YoY
Arvind Business Update
Arvind inaugurated a greenfield garment plant in Varanasi, its first in Uttar Pradesh. The plant is expected to employ over 1,000 people.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr